We are delighted to announce that Eagle IP has been recognized once more by IAM Patent 1000 - The World's Leading Patent Professionals - as a top ranked, “Highly Recommended Firm in Patent Prosecution”.

The IAM Patent 1000 is a respected annual directory dedicated to identifying leading patent firms and individual practitioners globally. Published by Intellectual Asset Management (IAM), the guide covers key jurisdictions and evaluates capabilities across the core areas of patent law. Inclusion in the directory is determined by a rigorous, independent research process that includes 900+ extensive interviews with in-house counsel, patent attorneys, and industry experts.

According to IAM, Eagle IP has carved out “a distinctive reputation for far-reaching and highly sophisticated patent protection” and “a prime pick for life sciences companies, research institutions and technology-driven enterprises navigating complex international patent strategies.”

IAM has further highlighted five individuals from our firm: Our President and Managing Director, Ms. Jennifer Che, Principal Ms. Yolanda Wang, Principal Ms. Pauli Wong, Dr. Jacqueline C Lui, Dr. Ho Chung Lui.

We are incredibly honoured to be included in this highest category among a select group of Hong Kong’s top IP firms. We are deeply grateful to IAM for this recognition of our work. At Eagle IP, we are dedicated to providing exceptional service to our clients by drawing upon our hands-on knowledge of US, Chinese, and Hong Kong patent laws, our proven ability to craft sophisticated and creative patent strategies, and our strong technical expertise. We will continue to build upon these strengths to deliver the highest level of service and support to the innovators who entrust us with protecting their groundbreaking ideas.

As always, a huge THANK YOU to all our clients, mentors, and colleagues who have supported us through the years.

Our Past Events

Recommended Insights

Do Promotional Marketing Materials Constitute an “Offer for Sale” under Chinese Patent Law? Bayer IP GmbH v. Nanjing Hang Seng Pharmaceutical

12 December 2023
Bayer's blockbuster drug Rivaroxaban has seen its share of patent litigations in China, several of which are big enough to be listed as Top 10 IP cases or 50 Representative IP cases. We summarized an invalidation case back in 2020 where all of Bayer’s claims directed towards the compound were upheld. Recently, another Rivaroxaban case […]

China Releases Details on Patent Term Extension, Deferred Examination and More in the Latest Draft Implementation Rules of the New Chinese Patent Law

11 December 2020
The China National Intellectual Property Administration (CNIPA) is moving forward at breakneck speeds aiming to get all the necessary pieces in place for the June 1, 2021 date when the new 4th Amendment of the Patent Law will come into effect. Most recently, this means a flurry of drafts coming out from CNIPA, including, but […]

Beijing IP Court Reverses CNIPA Decision and Upholds Ozempic® semaglutide patent in China as VALID based on Novo Nordisk’s Post Filing Data

27 June 2024
Recently, all eyes have been on China as the fundamental patent covering semaglutide, the active ingredient in Ozempic® and Wegovy®, will expire on March 20, 2026. It goes without saying that generics are ramping up bigtime in China (and also around the world), preparing to manufacture and sell this blockbuster drug to one of the […]

Can I transfer priority rights in China without the consent of other applicants? Insights from the Broad Institute’s CRISPR patent

4 February 2025
The high-profile disputes surrounding an important CRISPR patent belonging to The Broad Institute, MIT and Harvard (hereinafter “the proprietors”) has attracted a lot of attention in recent years, particularly regarding the validity of priority rights that were challenged worldwide. In Europe, the patent was famously revoked by the European Patent Office (hereinafter “EPO”) due to […]
Top crossarrow-right